Skip to main content
. 2022 Apr 3;14(4):783. doi: 10.3390/pharmaceutics14040783

Figure 7.

Figure 7

(A) AGN release profiles from the optimized AGN-PLHNPs and AGN suspension and (B) various kinetic models: (i) Zero-order model, (ii) First-order model, (iii) Higuchi matrix model, and (iv) Korsmeyer–Peppas model for optimized AGN-PLHNPs to understand the mechanism.

HHS Vulnerability Disclosure